2407378
Project Grant
Overview
Grant Description
Sbir Phase I: Aneurysm Sealing Device (ASD) for Endovascular Applications -The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in its revolutionary approach to treating abdominal aortic aneurysms (AAA), a significant health concern especially prevalent among the elderly. This project aims to introduce a novel device that promises to significantly lower the rates of aneurysm related complications and reduce the need for repeat invasive procedures, which are common with current treatments.
By potentially saving significant healthcare costs and reducing the frequency of medical interventions, the device presents a transformative solution that could ease the financial burden on healthcare systems and patients alike. Moreover, the project has the potential to expand access to life-saving treatments in underserved and remote areas, thus leveling the playing field in healthcare accessibility.
The commercial and societal implications of this innovation could spur economic growth through intellectual property generation and job creation, thereby contributing to the advancement of the biomedical engineering sector. This Small Business Innovation Research (SBIR) Phase I project seeks to address the limitations of current endovascular treatments for abdominal aortic aneurysms (AAA) by developing a new device that aims to completely seal the aneurysm sac, eliminating the risk of post-procedure endoleaks.
The research objectives include validating the device's adaptability to different aneurysm profiles and its compatibility with various aortic locations, ensuring broad patient applicability. The technical approach involves a compressible body unit designed for precision deployment and a dual function that allows for drug delivery post-deployment. The anticipated technical results include demonstrating the device's effectiveness in sealing aneurysms in a benchtop flow model, thereby setting the stage for potential regulatory approval.
This project represents a significant leap forward in the treatment of AAAs, offering a more reliable and versatile solution compared to existing methods. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
By potentially saving significant healthcare costs and reducing the frequency of medical interventions, the device presents a transformative solution that could ease the financial burden on healthcare systems and patients alike. Moreover, the project has the potential to expand access to life-saving treatments in underserved and remote areas, thus leveling the playing field in healthcare accessibility.
The commercial and societal implications of this innovation could spur economic growth through intellectual property generation and job creation, thereby contributing to the advancement of the biomedical engineering sector. This Small Business Innovation Research (SBIR) Phase I project seeks to address the limitations of current endovascular treatments for abdominal aortic aneurysms (AAA) by developing a new device that aims to completely seal the aneurysm sac, eliminating the risk of post-procedure endoleaks.
The research objectives include validating the device's adaptability to different aneurysm profiles and its compatibility with various aortic locations, ensuring broad patient applicability. The technical approach involves a compressible body unit designed for precision deployment and a dual function that allows for drug delivery post-deployment. The anticipated technical results include demonstrating the device's effectiveness in sealing aneurysms in a benchtop flow model, thereby setting the stage for potential regulatory approval.
This project represents a significant leap forward in the treatment of AAAs, offering a more reliable and versatile solution compared to existing methods. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. - Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23515
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Costa Mesa,
California
92626-4755
United States
Geographic Scope
Single Zip Code
Life Seal Vascular was awarded
Project Grant 2407378
worth $274,547
from National Science Foundation in July 2024 with work to be completed primarily in Costa Mesa California United States.
The grant
has a duration of 1 year and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Project Grant was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Aneurysm Sealing Device (ASD) for Endovascular Applications
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in its revolutionary approach to treating abdominal aortic aneurysms (AAA), a significant health concern especially prevalent among the elderly. This project aims to introduce a novel device that promises to significantly lower the rates of aneurysm related complications and reduce the need for repeat invasive procedures, which are common with current treatments. By potentially saving significant healthcare costs and reducing the frequency of medical interventions, the device presents a transformative solution that could ease the financial burden on healthcare systems and patients alike. Moreover, the project has the potential to expand access to life-saving treatments in underserved and remote areas, thus leveling the playing field in healthcare accessibility. The commercial and societal implications of this innovation could spur economic growth through intellectual property generation and job creation, thereby contributing to the advancement of the biomedical engineering sector.
This Small Business Innovation Research (SBIR) Phase I project seeks to address the limitations of current endovascular treatments for abdominal aortic aneurysms (AAA) by developing a new device that aims to completely seal the aneurysm sac, eliminating the risk of post-procedure endoleaks. The research objectives include validating the device's adaptability to different aneurysm profiles and its compatibility with various aortic locations, ensuring broad patient applicability. The technical approach involves a compressible body unit designed for precision deployment and a dual function that allows for drug delivery post-deployment. The anticipated technical results include demonstrating the device's effectiveness in sealing aneurysms in a benchtop flow model, thereby setting the stage for potential regulatory approval. This project represents a significant leap forward in the treatment of AAAs, offering a more reliable and versatile solution compared to existing methods.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-515
Status
(Complete)
Last Modified 6/20/24
Period of Performance
7/1/24
Start Date
6/30/25
End Date
Funding Split
$274.5K
Federal Obligation
$0.0
Non-Federal Obligation
$274.5K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2407378
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
N43EA8M7LGN3
Awardee CAGE
9RXG6
Performance District
CA-47
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 6/20/24